Full-Time

Vice President

Global Head of Patient Safety

Confirmed live in the last 24 hours

Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals

No salary listed

Expert

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Prior global leadership experience in a Patient Safety / Pharmacovigilance organization and broad R&D global functional experience and understanding
  • Credibility and reputation to attract and retain top talent with a history of creating teams that can thrive in a fast-paced, matrixed environment.
  • Ability to create and fulfill a vision in a matrix environment and work collaboratively with internal stakeholders across different functions.
  • Strong interpersonal skills that facilitate collaboration across functions to reach consensus on safety topics.
  • Ability to travel nationally and internationally as required.
  • MD degree and board certification or equivalent years of pharmacovigilance experience
  • 15+ years of biopharmaceutical industry drug development experience, early through late-stage development.
Responsibilities
  • Sets the overall safety strategy for all of the Gilead portfolio throughout the entire product lifecycle with input from various functions.
  • Establishes and maintains strong, collaborative relationships with all relevant internal stakeholders.
  • Ensures that the pharmacovigilance actions are aligned with disease area strategies and appropriate activities are prioritized.
  • Facilitates efforts across Development and is accountable for the technical execution of pharmacovigilance projects and deliverables across all therapeutic areas.
  • Champions initiatives that contribute to global process improvements.
  • Develops and provides mentorship to enable project teams to embrace pharmacovigilance initiatives and strategic remits.
  • Thinks creatively and brings innovative solutions to optimize the contribution of Patient Safety within Gilead.
  • Develops others by creating opportunities within the PS organization, fostering cross-functional exchanges, identifying and mentoring high performers and building a culture of continuous improvement and inclusion throughout the organization.
  • Advocates on behalf of Gilead and effectively communicates complex medical/clinical concepts in both written and oral communication to both internal and external stakeholders.
Desired Qualifications
  • Established track record as a strong clinical scientist, with expertise in translational medicine, real-world evidence, benefit-risk assessment and risk management.
  • Solid knowledge of pharmacovigilance operations and processes as well as national/regional differences and requirements (e.g., US FDA, EMA, PMDA).
  • Established reputation as a senior leader in the global pharmacovigilance ecosystem (e.g., participation in CIOMS, Navitas, Transcelerate).
  • Established reputation as a leader of a senior level team with a global footprint, managing across time zones and geographies.
  • Additional degree or hands-on training in epidemiology, biostatistics or related fields.
  • Broad career experience including academic medicine and industry experience in development, medical affairs and/or regulatory affairs.

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and ensure sustainable practices. The company's goal is to enhance health equity and access to care, working with communities globally to remove barriers to healthcare and make its medicines available to those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery is revolutionizing the biopharmaceutical industry, benefiting companies like Gilead.
  • Gilead's lenacapavir development represents a significant advancement in HIV treatment.
  • Investor confidence in Gilead is strong, as shown by recent investments.

What critics are saying

  • Layoffs at Gilead may disrupt strategic decision-making and operational efficiency.
  • Competition from AI-driven drug discovery companies could outpace traditional methods.
  • STAT6 program partnership with LEO Pharma may face challenges in clinical success.

What makes Gilead Sciences unique

  • Gilead's lenacapavir offers a once-yearly HIV prevention, enhancing patient adherence.
  • Strategic partnership with LEO Pharma expands Gilead's inflammation research portfolio.
  • Gilead's manufacturing efficiencies provide a competitive edge in CAR-T cell therapy production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

SFist
Apr 2nd, 2025
April Fool's Day Around the Bay: Bob Lee's Family Has Sued His Convicted Killer Nima Momeni

Foster City-based HIV drug company Gilead Sciences is laying off nearly 150 people, and the job cuts are significant among senior members of the company's management.

Labiotech
Mar 27th, 2025
12 Ai Drug Discovery Companies You Should Know About

Newsletter Signup - Under Article / In Page"*" indicates required fields Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the industry now embracing the technology, we take a look at 12 AI drug discovery companies. The COVID-19 pandemic revealed AI to be an essential tool in helping to find treatments and vaccines with greater speed and precision. Since then, there have been several drug discovery breakthroughs for AI within the biopharma industry, from helping to quickly and efficiently discover a new antibiotic called abaucin to combat a multi-drug resistant bacteria, to fully discovering and designing a drug that has entered clinical trials. Here are 12 AI drug discovery companies currently making great strides with their technology. Anima Biotech Technology: mRNA biology modulators Disease areas: Immunology, oncology and neuroscienceRecent news: Announced promising preclinical data for lead pulmonary fibrosis candidate Anima Biotech’s AI drug discovery technology is built around its mRNA Lightning.AI platform, which images hundreds of cellular pathways in both healthy and diseased cells to train disease-specific AI models, making use of neural networks to help these models distinguish between healthy and diseased cells and identify dysregulated pathways. These pathways are subsequently analyzed to uncover novel targets backed by experimental validation. Anima currently has 20 preclinical candidates being evaluated for immunology, oncology, and neuroscience indications, with its most advanced candidate indicated for the treatment of lung fibrosis. The company announced in February 2024 that this candidate had shown promising preclinical results and could open up new avenues for treating patients with idiopathic pulmonary fibrosis. The AI drug discovery company also has ongoing collaborations with several pharma giants. After initially partnering with Eli Lilly in 2018 and Takeda in 2021, its most recent partnership was formed with AbbVie in 2023 for the discovery and development of mRNA biology modulators against oncology and immunology targets. Atomwise Technology: TYK2 inhibitor  Disease area: Autoimmune and autoinflammatory diseasesRecent news: Published results showcasing AtomNet’s ability for drug discoveryAtomwise is leveraging the power of AI in an attempt to revolutionize small molecule drug discovery

Charities.org
Mar 25th, 2025
Sustainability News provided by 3BL

Gilead recently partnered with GRYT Health to host a New Lens on Lung Cancer workshop where people living with lung cancer and their loved ones shared their experience with stigma.

CSR Company
Mar 18th, 2025
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies

Gilead Sciences ranked in top five Most JUST list for biopharma companies.

Pipeline Review
Mar 12th, 2025
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

First clinical data for Gilead's investigational Once-Yearly Lenacapavir for HIV Prevention presented at CROI 2025 and published in The Lancet.